Company profile: PhosImmune
1.1 - Company Overview
Company description
- Provider of clinical-stage therapeutic cancer vaccines enabled by a library of unique, aberrantly phosphorylated tumor antigens (PTAs) directly implicated in metastasis, addressing the need for high-quality tumor antigens for use in new and more effective cancer vaccines.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PhosImmune
Vir Biotechnology
HQ: United States
Website
- Description: Provider of immunology-based products to treat and prevent infectious diseases and other serious conditions, including Phase 2 tobevibart + elebsiran for chronic hepatitis delta and elebsiran + PEG-IFN-α for chronic hepatitis B; Phase 1 VIR-1388 for HIV prevention; and preclinical candidates VIR-8190 (RSV & hMPV), VIR-2981 (influenza A/B), and VIR-1949 (pre-cancerous HPV lesions).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vir Biotechnology company profile →
Gliknik
HQ: United States
Website
- Description: Provider of therapies for patients with cancer and immune disorders, including recombinant Fc fusion proteins in clinical trials: GL-2045, aimed at treating autoimmune diseases by mimicking IVIG effects, and GL-0719, designed to selectively inhibit the classical and lectin complement pathways for autoimmune disease treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gliknik company profile →
Bright Peak Therapeutics
HQ: Switzerland
Website
- Description: Provider of immunotherapies for cancer and autoimmune diseases, enabling tissue- and cell-specific cytokine targeting with enhanced efficacy. Offerings include Bright Peak Immunoconjugates combining optimized cytokines with antibodies; a chemical protein synthesis platform for novel proteins; and candidates such as BPT567 (PD1-IL18), BPT331 (PD1-IL2), and BPT331CAPS (PD1-IL2CAPS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bright Peak Therapeutics company profile →
Nouscom
HQ: Switzerland
Website
- Description: Provider of an immunotherapy platform for cancer, creating modified viral vector vaccines with engineered vectors optimized to express long strings of tumor neoantigens; products: NOUS-209 (off-the-shelf for mismatch repair deficiency and microsatellite instability), NOUS-PEV (personalized vaccine encoding up to 60 neoantigens via VENUS), NOUS-THV-001 (oncolytic Herpes Virus expressing immunomodulatory molecules).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nouscom company profile →
InflaRx
HQ: Germany
Website
- Description: Provider of therapeutics for acute and chronic inflammation targeting the C5a/C5aR pathway, including vilobelimab, a monoclonal antibody for chronic inflammatory diseases, oncology and critically ill COVID-19, authorized for emergency use by the FDA in hospitalized adults requiring invasive mechanical ventilation or ECMO, and INF904, an oral C5aR inhibitor in development for chronic spontaneous urticaria and hidradenitis suppurativa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InflaRx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PhosImmune
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PhosImmune
2.2 - Growth funds investing in similar companies to PhosImmune
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PhosImmune
4.2 - Public trading comparable groups for PhosImmune
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →